Every material Form 8-K Quest Diagnostics has filed with the SEC since July 03, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Quest Diagnostics said on October 21, 2026 it learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and look up results. The company believes an unauthorized party accessed certain patient records, and the full scope is still under investigation. The company said the incident has not materially disrupted its business operations or its ability to serve patients.
Unauthorized access to Quanum LSM system discovered October 21, 2026
Company believes certain patient records were accessed; full scope under investigation
Federal law enforcement notified and external cybersecurity experts engaged
Company states business operations and patient service not materially disrupted
Quest Diagnostics reported third-quarter 2026 net revenues of $3.10 billion, up 10.0% from a year earlier, with reported diluted EPS of $2.78, up 28.7%, and adjusted diluted EPS of $3.00, up 15.4%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because the outlook for both revenue and earnings per share moved higher.
Q3 2026 net revenues of $3,097 million, up 10.0% from $2,816 million in Q3 2025
Q3 2026 reported diluted EPS of $2.78 vs. $2.16 a year earlier; adjusted diluted EPS of $3.00 vs. $2.60
Full-year 2026 reported diluted EPS now expected at $10.21 to $10.31, up from $9.97 to $10.17
Full-year 2026 net revenues now expected at $12.065 billion to $12.105 billion, up from $11.95 billion to $12.05 billion; the company will hold its 2027 Investor Day on March 25, 2027
Quest Diagnostics said Catherine T. Doherty will retire in July 2027 and will move to an Executive Vice President role effective November 1, 2026, overseeing health systems, its Corewell Health joint venture, and Project Nova. The filing states her base salary is unchanged at $650,000 and her incentive target remains 80% of base salary, with a new $1.2 million restricted stock unit award planned, so the change is a planned succession transition rather than an abrupt departure.
Catherine T. Doherty will retire in July 2027 and transition to Executive Vice President effective November 1, 2026.
Her responsibilities will include health systems, the Corewell Health joint venture, and Project Nova, a multi-year project to modernize Order to Cash business processes.
The Compensation and Leadership Development Committee approved no change to her $650,000 base salary or 80% incentive target.
A restricted stock unit award with a target value of $1.2 million has a grant date of November 3, 2026.
Quest Diagnostics reported second-quarter 2026 net revenues of $3.04 billion, up 10.2% from a year earlier, and reported diluted EPS of $2.84, up 15.0%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because it expects higher earnings for the year than it previously forecast.
Q2 net revenues $3.04 billion, up 10.2%, with 10.0% organic revenue growth
Q2 reported diluted EPS $2.84, up 15.0%; adjusted diluted EPS $3.12, up 19.1%
Full-year 2026 revenue guidance raised to $11.95 billion to $12.05 billion from $11.78 billion to $11.90 billion
Full-year adjusted diluted EPS guidance raised to $11.05 to $11.25 from $10.63 to $10.83; Q2 reported operating margin was 15.1% versus 15.9% a year earlier
Quest Diagnostics issued $500 million in aggregate principal of 5.000% senior notes due June 30, 2036, on May 6, 2026, under its existing 2001 indenture as supplemented. The notes are senior unsecured obligations that rank equally with the company's other senior unsecured debt, and the filing describes covenants limiting certain liens, sale and leaseback transactions, and mergers or asset transfers.
Principal amount: $500 million; interest rate 5.000%, paid June 30 and December 30, first payment December 30, 2026
Maturity: June 30, 2036; no sinking fund
Change of control triggering event requires an offer to repurchase at 101% of principal plus accrued interest
Exhibit 5.1 legality opinion from Allen Overy Shearman Sterling US LLP filed with the report
Quest Diagnostics reported first quarter 2026 net revenues of $2.90 billion, up 9.2% from a year earlier, and reported diluted EPS of $2.24, up 15.5%. The company raised its full year 2026 revenue and EPS guidance, which means higher expected results for shareholders than the prior outlook.
Q1 2026 net revenues were $2.90 billion, up 9.2%; Diagnostic Information Services revenues rose 9.4% to $2.83 billion
Q1 reported diluted EPS was $2.24, up from $1.94; adjusted diluted EPS was $2.50, up 13.1% from $2.21
Full year 2026 reported diluted EPS guidance was raised to $9.58 to $9.78 from $9.45 to $9.65; adjusted EPS guidance to $10.63 to $10.83 from $10.50 to $10.70
Cash provided by operations fell 11.6% to $278 million in Q1 from $314 million
Quest Diagnostics' board elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, as a director on March 9, 2026, and appointed him to its Compensation and Leadership Development Committee and Quality and Compliance Committee. The board board has eleven members including Mr. Wentworth, and it determined he is independent under NYSE standards. The filing does not report any financial results or guidance.
Board election effective March 9, 2026; board now has eleven members
Mr. Wentworth, 65, previously was CEO of Walgreens Boots Alliance, founding CEO of Evernorth Health Services and CEO of Express Scripts
Received a prorated one-time restricted share unit grant valued at approximately $43,000
Named to Compensation and Leadership Development Committee and Quality and Compliance Committee
Quest Diagnostics reported fourth-quarter and full-year 2025 results with double-digit full-year growth in revenue and EPS, and issued 2026 guidance for net revenues of $11.70 billion to $11.82 billion. The board also raised the quarterly dividend 7.5% to $0.86 per share and added $1 billion to its share repurchase authorization, which matters to shareholders because it increases cash returned to them.
Full-year 2025 net revenues were $11.04 billion, up 11.8%, and reported diluted EPS was $8.75, up 13.8%.
Fourth-quarter revenues were $2.81 billion, up 7.1%, and adjusted diluted EPS was $2.42, up 8.5%.
2026 guidance: reported diluted EPS of $9.45 to $9.65 and adjusted diluted EPS of $10.50 to $10.70.
Quarterly dividend rises from $0.80 to $0.86 per share, payable April 20, 2026 to holders of record on April 6, 2026; repurchase authorization increased by $1 billion.
Quest Diagnostics filed a presentation from its January 12, 2026 appearance at the 44th Annual J.P. Morgan Healthcare Conference, where Chairman, CEO and President Jim Davis discussed strategy and market trends. The filing contains no new quarterly results, but it restates a long-term outlook for revenue, adjusted EPS and capital deployment through 2027.
Long-term outlook beyond 2025: 4% to 5% revenue CAGR and 7% to 9% adjusted EPS CAGR, with operating margins up 75 to 150 basis points by the end of 2027.
Targeted capital deployment for 2025 to 2027 includes $4.5 billion to $5.0 billion in operating cash flow and $3.0 billion to $3.3 billion in free cash flow.
Planned uses include about $1.5 billion for acquisitions, about $1.0 billion for dividends and about $0.7 billion for share repurchases.
The presentation says the capital deployment plan is consistent with what the company shared at its March 2025 Investor Day.
Quest Diagnostics reported third-quarter 2025 revenue of $2.82 billion, up 13.1% from a year earlier, and reported diluted EPS of $2.16, up 8.5%. The company raised its full-year 2025 revenue and adjusted diluted EPS guidance, but its reported diluted EPS range was lowered at both ends.
Q3 2025 net revenues of $2.82 billion, up 13.1%, including 6.8% organic growth; adjusted diluted EPS of $2.60, up 13.0%
Full-year 2025 net revenue guidance raised to $10.96 billion to $11.00 billion from $10.80 billion to $10.92 billion
Full-year reported diluted EPS guidance now $8.58 to $8.66, versus $8.60 to $8.80 previously; adjusted diluted EPS guidance raised to $9.76 to $9.84 from $9.63 to $9.83
Agreement with Corewell Health to form a lab services joint venture in Michigan; Co-Lab Solutions annual revenues expected to reach about $1 billion next year
Quest Diagnostics reported second-quarter 2025 revenue of $2.76 billion, up 15.2% from a year earlier, and reported diluted EPS of $2.47, up 21.7%. The company raised its adjusted full-year 2025 EPS outlook to $9.63-$9.83 and its net revenue outlook to $10.80 billion-$10.92 billion, but narrowed its reported EPS outlook to $8.60-$8.80, which is lower than the prior $8.62-$8.87 range.
Q2 2025 net revenues $2.76 billion, up 15.2%; organic revenues grew 5.2%, per the CEO's statement
Q2 diluted EPS $2.47 vs. $2.03 a year earlier; adjusted diluted EPS $2.62 vs. $2.35
Full-year 2025 adjusted diluted EPS raised to $9.63-$9.83 from $9.55-$9.80; reported diluted EPS lowered to $8.60-$8.80 from $8.62-$8.87
Year-to-date cash from operations $858 million, up 67.1%
Quest Diagnostics reported first quarter 2025 revenue of $2.65 billion, up 12.1% from a year earlier, and reported diluted EPS of $1.94, up 12.8%. The company raised its full-year 2025 reported diluted EPS outlook to $8.62 to $8.87 from $8.34 to $8.59 and reaffirmed its revenue and adjusted EPS guidance, which matters to shareholders because the earnings outlook moved up while the top-line outlook held.
Q1 2025 net revenues $2.65 billion, up 12.1%; organic requisition volume fell 0.9%
Reported diluted EPS $1.94, up 12.8%; adjusted diluted EPS $2.21, up 8.3%
Full-year 2025 reported diluted EPS now expected at $8.62 to $8.87, up from $8.34 to $8.59
Full-year 2025 revenue guidance of $10.70 billion to $10.85 billion and adjusted diluted EPS of $9.55 to $9.80 unchanged
Quest Diagnostics reported fourth quarter 2024 revenue of $2.62 billion, up 14.5%, and reported diluted EPS of $1.95, up 14.7%, with full year revenue of $9.87 billion, up 6.7%. The company gave 2025 reported diluted EPS guidance of $8.34 to $8.59 and raised its quarterly dividend 6.7% to $0.80 per share. Shareholders see higher reported earnings in 2024, a 2025 outlook above the 2024 reported EPS of $7.69, and a larger dividend.
Q4 2024 reported diluted EPS $1.95 vs. $1.70 in Q4 2023; adjusted diluted EPS $2.23, up 3.7%
Full year 2024 revenue $9.87 billion, up 6.7%; full year reported diluted EPS $7.69, up 2.7%
2025 reported diluted EPS guidance $8.34 to $8.59; adjusted diluted EPS guidance $9.55 to $9.80
Quarterly dividend raised from $0.75 to $0.80 per share, payable April 21, 2025, record date April 7, 2025
Quest Diagnostics reported third-quarter 2024 net revenues of $2.49 billion, up 8.5% from a year earlier, and reported diluted EPS of $1.99, up 1.5%. The company raised its full-year 2024 revenue outlook to $9.80 billion to $9.85 billion, citing recent acquisitions including LifeLabs, while keeping the midpoint of its adjusted EPS outlook unchanged.
Q3 2024 net revenues $2.49 billion, up 8.5%; organic growth 4.2% per CEO Jim Davis
Q3 operating income $330 million, down 3.3% from $342 million; adjusted diluted EPS $2.30, up 3.6%
2024 revenue guidance raised to $9.80 billion–$9.85 billion from $9.50 billion–$9.58 billion
2024 reported diluted EPS guidance narrowed to $7.60–$7.70; adjusted EPS guidance $8.85–$8.95 from $8.80–$9.00
Quest Diagnostics issued $1.85 billion of senior notes in three tranches due 2027, 2029 and 2034, with the offering priced on August 15, 2024 and closing on August 19, 2024. The company said it intends to use the proceeds mainly to fund the purchase price of its previously announced LifeLabs acquisition, which adds debt tied to that deal.
$400 million of 4.600% senior notes due December 15, 2027, $600 million of 4.625% notes due 2029, and $850 million of 5.000% notes due 2034
If the LifeLabs acquisition is not completed by the Termination Date, the 2027 and 2029 notes must be redeemed at 101% of principal plus accrued interest; the 2034 notes remain outstanding
Interest is paid June 15 and December 15 each year, beginning December 15, 2024
Quest Diagnostics reported second-quarter 2024 net revenues of $2.40 billion, up 2.5% from a year earlier, and raised its full-year 2024 revenue and adjusted diluted EPS guidance. Reported diluted EPS fell 1.0% to $2.03, while adjusted diluted EPS rose 2.2% to $2.35, so shareholders see higher sales and adjusted earnings alongside lower reported profit. The updated guidance excludes the pending LifeLabs acquisition.
Q2 2024 net revenues $2.40 billion, up 2.5%; net income attributable to Quest Diagnostics $229 million, down 2.4%
Q2 reported diluted EPS $2.03, down 1.0%; adjusted diluted EPS $2.35, up 2.2%
Full-year 2024 net revenues now expected at $9.50 billion to $9.58 billion, up from $9.40 billion to $9.48 billion
Full-year adjusted diluted EPS now expected at $8.80 to $9.00, up from $8.72 to $8.97; reported diluted EPS range $7.57 to $7.77, high end down from $7.82
Quest Diagnostics signed an agreement on July 2, 2024 to acquire LifeLabs, a Canadian provider of laboratory diagnostic services, from OMERS for about 1.35 billion Canadian dollars (about $985 million U.S.), including net debt. The company expects to fund the deal with cash on hand and debt, and expects it to close by the end of 2024, subject to customer consents and Canadian regulatory approvals.
Purchase price is about CAN $1.35 billion (about USD $985 million), including net debt, subject to customary adjustments.
The company expects the deal to add about CAN $970 million (about USD $710 million) in annual revenue.
Quest expects the deal to be slightly dilutive to GAAP EPS but accretive to adjusted EPS in the first 12 months after closing.
Closing is expected by the end of the year and depends on customer consents and Competition Act and Investment Canada Act conditions.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Quest Diagnostics filing is on SEC EDGAR ↗. 8-K briefs of other companies →